Processing

Please wait...

Settings

Settings

Goto Application

1. CN103648585 - 基于多肽辐射毒性血清标记的处置规划

Office
China
Application Number 201280032115.8
Application Date 29.06.2012
Publication Number 103648585
Publication Date 19.03.2014
Grant Number 103648585
Grant Date 16.11.2018
Publication Kind B
IPC
G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
A61N 5/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
5Radiation therapy
10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
G01N 33/574
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
A61N 5/1039
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
5Radiation therapy
10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
103Treatment planning systems
1039using functional images, e.g. PET or MRI
G01N 33/57434
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57407Specifically defined cancers
57434of prostate
G01N 33/6851
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6803General methods of protein analysis not limited to specific proteins or families of proteins
6848Methods of protein analysis involving mass spectrometry
6851Methods of protein analysis involving laser desorption ionisation mass spectrometry
G01N 2800/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
50Determining the risk of developing a disease
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 2800/60
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
60Complex ways of combining multiple protein biomarkers for diagnosis
Applicants 皇家飞利浦有限公司
Inventors K·比特
C·里宾
Agents 永新专利商标代理有限公司 72002
永新专利商标代理有限公司 72002
Priority Data 61/502,960 30.06.2011 US
Title
(ZH) 基于多肽辐射毒性血清标记的处置规划
Abstract
(ZH)
一种方法包括如下操作中的至少一种:基于指示在处置计划的多个放射治疗处置中的至少一个的之前或之后中的至少一个时间处的患者的辐射毒性的所述患者的一组血清多肽,建立或调整所述患者的所述处置计划,其中,所述辐射毒性是由来自所述放射治疗处置的辐射暴露诱发的。一种系统包括处置规划设备(108),所述处置规划设备方便了如下至少一项操作:基于指示患者对来自放射治疗的辐射的高风险或早期辐射毒性的所述患者的一组血清多肽的量或浓度,为所述患者建立或调整处置计划。

Related patent documents